We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.175 | -5.30% | 3.125 | 3.00 | 3.25 | 3.125 | 3.075 | 3.08 | 576,496 | 14:00:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.47 | 148.71M |
Date | Subject | Author | Discuss |
---|---|---|---|
20/8/2019 17:42 | Was that Skygem picking up a few more? | ewanwhose | |
01/8/2019 15:52 | Brexit nerves impacting? | jimmyloser | |
17/7/2019 18:38 | ... But not quite enough to top up... | ewanwhose | |
17/7/2019 11:45 | Bit of a sharp pull back.... | audigger | |
11/7/2019 07:21 | Video from FD Nick Wykeman re: this mornings trading update: | macc1 | |
27/6/2019 14:24 | Looks almost back to where we started yesterday. Disappointing end to the day | richsawko | |
27/6/2019 10:50 | Didn't see that coming. Certainly reinforces the belief that the management team are on top of things. Proving to be a bit of a roller coaster ride this year! What would be impressive is if they can pull a rabbit out of the hat with a more favourable interpretation of the B301 Phase III trial for the birch product. | audigger | |
27/6/2019 08:03 | Plenty of cash and can we dare hope for a bottom-line profit? | ewanwhose | |
27/6/2019 07:15 | Breaking news Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. ("Inflamax") in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16. Inflamax has also agreed to pay a substantial part of the Group's legal costs. The clinical trial (G204) used mobile challenge chambers provided by Inflamax and preceded the successful Grass MATA MPL trial (G205) which the Group reported in June 2018. The Group commenced legal proceedings in the English High Court against Inflamax in March 2017 for breach of contract and misrepresentation concerning the G204 Study. Commenting on outcome, Manuel Llobet, CEO of Allergy Therapeutics, said: "ATL has always had full confidence in the Grass MATA MPL product and maintained that the inconclusive results of the G204 study were due to the inadequate procedures in the study. I am pleased that Inflamax have now compensated ATL for a significant proportion of the wasted study costs, as well as agreeing to pay the majority of the legal costs. Allergy Therapeutics aims to maintain the highest standards throughout its business and we are pleased that the matter has now been resolved." | jimmyloser | |
25/6/2019 11:25 | About time Skygem topped up. | ewanwhose | |
14/6/2019 08:19 | On Thursday Liu Xiaoming, China's ambassador to the UK, said that excluding Huawei from Britain's 5G network would "send a very bad signal". However, weak sterling gives Chinese investors an opportunity to buy more UK assets, says Monique Wong of Coutts. Chinese investment in the UK has largely been focused on the commercial property sector - "the iconic Cheesegrater was sold to Chinese investors a couple of years ago for just over a billion pounds", she says. "And don't forgot sterling is cheap, " she said, about 10% cheaper against the Chinese currency since the referendum. "It is an opportunity for Chinese investors and international investors more broadly," she said, adding that China's Fosun has expressed an interest in buying Thomas Cook's tour business. She also had a view on why was the market impact of the Hong Kong protests was limited - the Hang Seng stock index was down less than 0.5%. She said: "Usually the protests blow over... it doesn't really change our view on the region". | jimmyloser | |
11/6/2019 13:45 | @jimmyloser Is Woodford buying in? If he was, the price would nosedive: maybe he's shorting it? | andrewbaker | |
11/6/2019 07:03 | See above......Somebody likes the taste of peanuts. 15% of AGY for circa 11p a share !!! | jimmyloser | |
07/6/2019 10:49 | Here we go again....are the Chinese investors looking for more than peanuts? | jimmyloser | |
06/6/2019 11:07 | Chinese peanuts! | jimmyloser | |
05/6/2019 17:35 | Well done Jimmy, very funny!!! :-) | nquaile875 | |
05/6/2019 15:46 | Is Woodford buying in? | jimmyloser | |
03/6/2019 19:19 | A few positive words on peanuts over the next few days would not go amiss. | jimmyloser | |
03/6/2019 12:39 | Good to see some buying today. Can't see any news anywhere. | ewanwhose | |
20/5/2019 07:22 | Indeed thew mention of China appears a new line form the PR gurus they employ. Encouraging but early days yet and we know how perilous the journey can be. Would be good if it gave the share price another small jolt north | audigger | |
20/5/2019 07:06 | A little encouraging news this morning from AGY and am I alone in noting the CHINA gets a first mention as a potential market? | jimmyloser | |
15/5/2019 13:41 | Hmm....I wonder what is going on? Wonder what the detailed history is of ZQ investments internationally over time? | blather1 | |
15/5/2019 13:24 | There is a hierarchy of ZQ companies who own a hierarchy of Skygem companies - they are listed in the RNS | ewanwhose | |
15/5/2019 13:16 | So a total of close to 30% of all AGY shares were snapped up in three (think it was three) momentous buys on one day and only part of those trades were accounted for by ZQ as mentioned in the RNS. Is Skygem and ZQ the same entity? | blather1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions